佩蒂股份 reported revenue of ¥0.73B for the period ended 2026-06-30, +1.0% year on year. Net income was ¥0.03B, a 3.4% net margin on a 28.4% gross margin. The largest revenue line is 植物咬胶 at 35% of the total. Free cash flow for the period was ¥-0.03B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.73B | +1.0% |
| Gross profit | ¥0.21B | — |
| Operating income | ¥0.03B | — |
| Net income | ¥0.03B | -68.5% |
| Gross margin | 28.4% | Net margin 3.4% |
| Revenue Q/Q | +9.3% | — |
| Segment | Revenue | Share |
|---|---|---|
| 植物咬胶 | ¥0.26B | 35.2% |
| 营养肉质零食 | ¥0.23B | 31.0% |
| 畜皮咬胶 | ¥0.18B | 25.2% |
| 主粮和湿粮 | ¥0.06B | 8.1% |
| 其他主营业务 | ¥0.00B | 0.6% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.53B | 71.6% |
| R&D | ¥0.02B | 2.3% |
| SG&A | ¥0.13B | 17.1% |
| Tax & other | ¥0.01B | 1.1% |
| Item | Amount |
|---|---|
| Total assets | ¥2.82B |
| Total liabilities | ¥1.00B |
| Shareholders' equity | ¥1.83B |
| Equity / assets | 64.7% |
| Operating cash flow | ¥-0.01B |
| Capital expenditure | ¥0.02B |
| Free cash flow | ¥-0.03B |
| Cash conversion (OCF / net income) | -263% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
宇信科技 ・ 建科院 ・ 华大基因 ・ 英科医疗 ・ 中科信息 ・ 电连技术 ・ 隆盛科技 ・ 英搏尔 ・ 朗新科技 ・ 海特生物 ・ 中石科技 ・ 艾德生物
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies